2023-12-31-accounts

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 Charlty Reglstratlon No. 1183890 (England and Wales) Charlty Reglstratlon No. SC049802 Iscotlandl Company Registration No. 11911752 (England and Wales) LEUKAEMIA CARE ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Leukaemia Care WVdW.leukaemiacare.o

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE LEGAL AND ADMINISTRATIVE INFORMATION Patrons Lady Penny Mountbatten Beverley Warboys Trustees Mr Christopher R G Matthews-maxwell (Chairl Mrs W J Davies (Treasurer) Dr Emmanouil Nikolousis Ms E Wilson (Vice Chairl Ms Kate Stallard Mr Robert Heppell Mr Dharmesh Mehta Professor Mhairi Copland Ms Carina Patterson Helen Knight Dr Sarah Searfe President Dr Richard Taylor Vlce Presldents Ms Sue Merchant Mr Roland Maturi Professor Claire Harrison Dr Robert Marcus Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr C.R.G. Mallhews-maxwell Mr Peter Mondon MrAnlhony Gavin Senior ManagementTeam Chief Executive Officer Chief Executive Officer Chief Operating Officer and Deputy CEO Communications and Fundraising Director Colin Dyer Zack Pemberton-v￿hlteIeY Monica Izmajlowcz Nicole Scully lappoinled 02104120241 (resigned 30111120231 Medical Advisory Panels As described in the Trustees, Report Secretary Monica Izmajlowcz Charlty number (England and Wales) 1183890 Charlty number Iscotlandl SC049802 Company number 11911752 Website WM￿.leUkaernI3care.Org.uk Registered office One Birch Court Blackpole East Worcester 38SG

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE LEGAL AND ADMINISTRATIVE INFORMATION Audltor Kendall Wadley LLP Granla Lodge 71 Graham Road Malvem Worcestershire WR14 2JS Bankers Barclays Bank Hc 54 High Street Worcester WR1 2QQ Sollcltors Harrison Clark Rickerbys 5 Deansway Worcester WR1 2JG Investment advisors Titan Private Wealth Lirniled 2 Greengale Cardale Park Harrogate HG3 1GY CCLA Senator house 85 Queen Victoria Street London EC4V 4ET Brewn Dolphin 12 Smithfield Street London EC1A 9BD

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE CONTENTS Page Trustees, report 1-20 Slalement of trustees, responsibilities 21 Independent auditorfs report 22-24 Slalement of consolidated financial aclwilies 25 Slalement of financial activities- charity 26 Consolidated Balance sheet 27-28 Charity Balance sheet 29-30 Slalement of cash flows 31 Notes to the financial slalemenls 32-55

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS, REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023 The trustees present their annual report and financial ststemenls for the year ended 31 December 2023. The financial stslemenls have been prepared in accordan￿ wth the accounting policies sel out in note 1 to the financial slalemenls and Comply wth the charitable group's memorandum & articles of association, the Companies Act 2006, the Charities and Trustee Investment Iscollandl Act 2005, the Charities Accounts IScoll8ndl Regulations 2006 las amended) and Accounting and Reporting by Charities." Slalement of Recommended Practice applicable lo charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021" leffeclive 1 January 20191. Objectives and activities About us Leukaemia Care is the UK'S leading leukaemia charity. For over 50 years, we have been dedicated to ensuring that everyone affected receives the best possible diagnosis, information, advice, treatment and support. We are here for everyone affected by leukaemia and related blood cancer types syndromes IMDSI and myeloproliferalive neoplasms IMPNI. such as myelodysplastic Purpose The charity's objects are set out in its Articles of Association.. 1. The relief of sickness and the promotion and protection of good health among persons suffering from leukaemia and allied blood disorders. 2. The relief of need among families, carers and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or ¥who musl conlemplale the prospect of Irealmenl where those needs are attributsble lo the affliction of leukaemia and allied blood disorders. Our vision - our long-tsrni ideal A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, Irealmenl and support. Our mlsslon - What we are dolng to make that vlslon a reallty We exist lo improve the lives of everyone affected by leukaemia, MDS and MPN. We provide infomiation, advice and support for anyone affected, this includes patients and their friends and families too. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising public awareness. improving Servi￿$, and ensuring access to effective treatments. Bul most importantly, we bring people together and unite them behind our common goal. Together, we will create the future we all believe in.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Why ourwork is important To paint a picture of the scale of the issue across the UK.. • Leukaemia is the 12th most common form of cancer and 12th biggest Cancer killer. Every year, 10,000 people are diagnosed with leukaemia in the UK. Every year, 5,000 people die from leukaemia in the UK. Every year 6,000 people In the UK will be diagnosed with conditions that may develop into leukaemia, induding myelodysplaslic syndromes IMDSI and myeloproliferalive neoplasms IMPNI. Over 50,000 people are living with leukaemia in the UK. There are 34,000 people living with MDS or MPN in the UK. Our Strateglc Goals Our organisalional strategy focuses on the future we believe we can create and sets five clear goals for the work we rill be doing until 2030 to make this a reality sooner.. 1. Improving diagnosis- through awareness and early detection. 2. Ensuring everyone receives high quality infomiation, advice and support. 3. Tackling issues that impact people's lives. 4. Advancing treatment and care. 5. Creating a narrative lo better reflect the reality people experience. Bul we need your help. If you believe in the future we are trying lo create and want lo help us get there faster, please gel involved. For more information on our five goals, please visit our website www.I Publlc benefft Leukaemia Care provides public benefit as a charity IhrDugh all the charitable information, advice and support service areas detailed above. The Trustees have complied with their duly in accordance ￿rith the Charities Act 2011 to have due regard to the Charity Commission's guidance when reviewng the charity's aims and objectives, approving funding for projects and services, and in planning and undertaking current and future activities. Taking the Charity Commission's guidance into consideration, the Trustees are satisfied that our public benefit requirements have been met. As examples, our work delivers public benefit by providing information, advice and support lo anyone affected by leukaemia diagnosis,. patients, family members, friends as well as employers and schools looking for advice on how best lo support employees and students. This information and support helps people lo live better wlh their leukaemia by reducing the Isolation that can come with a blood cancer diagnosis, clarity on their Ireatrnenl options and Improving quality of life with strategies to redu￿ the impact of the side effects of treatment. Our Hashtsgspot Leukaemia campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak wth their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment. Our training raises awareness of the signs and symptoms of leukaemia among GPS and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment. Our nurse training provides much needed free training on aspects of caring for blood cancer patients thus enhancing their care.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Achlevoments and performan¢9 Executive summary 2023 was officially the Year of the Unicom. Two years in the planning. Unicornfesl - Leukaemia Care's public art trail in Bristol was a challenging new endeavour to raise funds for and raise awareness of leukaemia and LeLJkaemia Care. In temis of awareness, people of all ages were engaged in the aty of Bristol throughout the trail and with the Farewell Festival with overwhelmingly positive feedback re￿ived. Some of the specific numbers include.. 339,083 scans of unicorns by visitors, 25,900 downloads of the app, 489,657 website views, 9,000 farewell festival attendees and repealed press coverage including BBC, ITV and many other publications. As a result, 67% of trail goers said they were more aware of Leukaemia Care because of the trail, and S2.￿ said they were likely lo support Leukaemia Care in the future. It was a strong year for service delivery with investment from reserves allowing us to address rising demand for our patient services as shown in the Charitable Programmes Summary below. Recognising the importance of high- quality information lo patients, families and the healthcare professionals looking after them, and our expanding portfolio of booklets, we formed a dedicated Information team and appointed an experien￿￿ Infomiation Manager to help us refine our strategy. We continue to work closdy with Leukaemia UK on raising awareness of thè signs and symptoms of leukaemia with our Spot Leukaemia campaign and are an active member of the influential Blood Cancer Alliance. Our engagement writh supporters has improved, with over 400 respondents in our annual survey. We are grateful that so many people look the lime to complete il and give us their feedback we will be using it lo inform our strategy in 2024 and beyond. Fundraising continues lo be challenging, vAth the art trail and other areas not reaching anlicipaled levels and developing income streams needing longer lo come lo fruition. This meant a greater investment from reserves than anticipated for 2023 and will be reflected in plans for 2024 and 2025. The Trustee Board remain committed lo investing in servi￿$ and growing income lo meet increasing demand. However, when it became apparent that we were not going lo reach those anticipated ftjndraising levels. savings in expenditure began lo be planned across the charity which may also impact work in 2024. After nine years of Servi￿ in various roles, our CEO, Zack Pemberton-whiteley left for new opportunities in De￿Mber. Our COO and Diredor of Comms and Fundraising stepped in as joint Interim CEOS, and a new CEO was appointed in April 2024. Charitable Programmes Summary A breakdown of achievements against our five organisational goals is available in our Strategic Update section below. All funds assigned to Leukaemia Care's charitable services during the year were consistent with those goals sel out in our The Futu￿ We Will Create Together strategy Ipublished in 2022 and available al www.leukaemiacare.or .ukl. Examples of the allocation of those funds and the continuing increase in demand for our patient services include.. The provision of essential information wlh 34,259 information booklels128,800 in 20221 either ordered as printed copies or downloaded directly from the Leukaemia Care website, and 2,905 welcome packs11,005 in 20221 sent lo people newly engaged wth the charity. The charity's information helpline supported 1,192 people (compared to 906 in 20221. The work of our Welfare Officer who helped 301 people 1217 in 20221, and our Advocacy Officer who supported 204 people 1266 in 20221. 819 hardship grants 1465 in 20221 were made and a further 30 families were given financial or accommodation support for CAR-T treatment, thanks in no small part to our partnership with Dalata Hotels. Our Hospital Support Workers helped 583 people 1199 in 20221, a further 2,397 people 11,911 in 20221 attended 39 support groups, and 4,900 people were connected through our online forums14,333 in 20221. The Leukaemia Care Buddy scheme matched 148 people 1131 in 20221, while counselling was provided for 63 patients156 in 20221.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 In temis of reach, our Why Spot Leukaemia video was viewed 1.85m limes, and we ￿8¢hed 1.7billion people through 147 national and 323 regional pieces of media coverage along with our extensive online activity. Flnanclal summary 67 per ￿nt of the charity's income was allocated to our charitable services and projects in 2023 compared 10 56 per cent in the previous year. The total income raised during the year was £2,263,2491£2,139,494 in 20221 against expenditure of £2,860,8351£1,979,542 in 20221. Investment of £566,954 was made from the strategi¢ implemenlalion fund against a planned deficit of £468,272 which was £98,682 higher due lo lower than anticipated performance in some areas of fundraising. Total reserves stsnd at £2,573,092 of which £148,342 are restricted and £2,424,750 are unrestricted. thin the unreslricled funds is a designated fund called the 'Slrategi¢ Implementation Fund, which, al year end, stands St £227,528. This fund was designated lo support the two-year strategy agreed by the Board of Trustees in January 2024. Strateglc update for 2023 Includlng our plans for 2024 We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, infomiation, advice, treatment and support. Our organisational strategy focuses on the future we believe we can create and sets five clear goals for the work we TAriII be doing until 2030 to make this a reality sooner. For more information on Dur five goals, please visit our website www.leukaemiacare.or .uk This report sets out Leukaemia Care's achievements in each of these priority areas during 2023, along wth the charity's goals for the year ahead. Goal 1- Improving diagnosis- through awareness and early detsction We achieve this through our annual SpolLeukaemia campaign, largeling awareness days like World Leukemia Day and through our education work with GPS and other healthcare professionals. In 2023 we continued our collaboration with Leukaemia UK on the Spot Leukaemia Campaign, focusing on raising awareness of the symptoms of leukaemia. We soft-launched at the end of August with our new creative video (Why Spot Leukaemial which encourages people to aC￿sS their inner child and ask why when they notice symptoms such as fatigue, repeated infections, bruising and bleeding, to then see their GP and ask for a blood test. The video was viewed 1.85 million times. In 2024, we will review the Spot Leukaemia collaboration with Leukaemia UK, now in ils fourth year, to determine its long-temi direction and impact. Throughout the year, we ran mini campaigns on awareness days such as World Leukemia Day, MDS Day, Know AML Day and World Cancer Day. We look part in 11 blood cancer awareness days sharing 50 patient stories across different leukaemias, MDS and MPN. World Leukemia Day 14 September) which was launched by Leukaemia Care in 2020 in partnership with woddwide patient advocate groups reached 28.3 million people in 2023 130.1 million in 20221 on social media. Uptake of our GP online learning modules via the Royal College of General Praclilioners IRCGPI and Gateway C increased in 2023 1233 in 2022 vs. 340 in 20231. A further 87 GPS allènded our two webinars, which were both rated as very good by attendees. We continued lo attend and exhibit al conferences aimed al GPS such as the Best Practice, Guidelines and the RCGP annual conference with all contacts receiving follow-up information from us. In 2024. we will do a complete review of our GP education to produce recommendations on what we could do better lo raise awareness of leukaemia signs and symptoms with GPS.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Goal 2- Ensuring everyone receives high quality information, advice and support Leukaemia and blood cancer Is highly complex. We know that al diagnosis people are significantly less likely to understand what is wrong with them than for other forms of cancer. Many are left worried and confused. We know that high quality information, advice and support is key. Whilst most people receive information about their blood cancer, few receive information about emotional, practical and financial support. This area of work covers our core frontline services for patients and their families. Our written information (hard copy and onlinel, videos, podcasts, webinars and conferences. Our advice Servi￿ incorporates the helpline. VVhatsApp, email, advocacy casework and welfare advice, and hospital hubs. OLJr support services., support groups. Dnline forums, one to one buddy support, financial grants, counselling and free wills. As the range and volume of patient information produced by Leukaemia Care increases, we appointed an Infomiation Manager to ensure we continue to provide good quality information. In 2023, we focused on updating our patient infomiation as and when il came up for review. We updated our MDS booklet in collaboration with MDS UK and released a factsheel alongside it. We continue to offer our existing booklets alongside the new formals and in 2023, distributed 15,706113,862 in 20221 hard copies and 18,553 115,118 in 20221 free copies were downloaded from our shop. We also maintained our accredilalion with the PIF Tick scheme for patient information, ensuring our irrformalion continues lo be produced and reviewed in a robust way. We recogni2e that people like to access information in different formals. not just booklets, and that many would like an introduction to our services. We sent out 2,90511.005 in 20221 Welcome Packs introducing people lo our services and signposting them to our booklets, blogs, monthly podcast, videos and webinars. We ran 15120 in 20221 webinars on a variety of topics which were all recorded so they can be accessed time and lime again for people looking for information and debate on key topics such as women's health, CLL and living well on watch and wail, our "understanding series (hairy cell leukaemia, MPN, ALL, CMLI, vaccinations when living with leukaemia, MPN and MDS. Our webinars were viewed 11,429116,352 in 20221 times on social media. Alongside our information, we offer the opportunity to seek advice and support from our clinical nurse specialists. trained advocates and welfare advisors. We provided 1,192 people1906 in 20221 with timely advice and support via our helpline, WhalsApp and email with an average feedback score of 4.75 out of 5. Our Advocacy Caseworker supported 204 people 1266 in 20221 with issues such as employment rights, earfy retirement, travel insurance, COVID-19 related-queries and non-COVID vaccines. They work closely with our Welfare OffI￿r as many people have varied and complex needs that also affect finances. The number of advocacy queries has been lower overall this year in comparison to 2022 because of a fall in the number of COVID-19 queries that we receive, as some patients become more confident in managing their risk wthout our guidance. Despite a lower number of cases, there has been an Increase in more complex queries that have required more in-depth casework, working directly with patients lo support them wth issues such as employment and housing. Our welfa￿ Officer supported 301 1217 in 20221 people with most queries being Classed as major i.e. complex, helping people lo apply for benefits, support with housing, challenge benèfits decisions, apply for grants of money and goods and processing applicants for our Financial Hardship Fund, Exceptional Hardship Fund and CAR-T Away from Home Fund. "This PIP approval is a game-changer, opening doors lo assistance from my looal Council and occupational therapists. I cannot express enough g￿titUde foryour unwavering support. Without your and Leukaemia Care s guidance, this wouldn t have been achievable. Your encOu￿geMent and advice have been an absolute lifeline." Patient Towards the end of 2023, we set up four new hubs in Gwent, Plymouth, Bournemouth, and Norfolk. We also ran a pilot hub ¥Mth the Queen Elizabeth Hospital in Birmingham for a year which sadly was not extended.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Our other locations are Solihull Hospitsl Iwesl Midlands), Heartlands Hospital IBirminghaml, Sl James Hospital ILeedsl, Southampton General, University of Bristol Hospital, The Christie Imancheslerl, University College London Hospitsl, and Freeman Hospital, Newcasde. Our hospital support workers provide emotional support, information and advice lo patients and their families within haemalology departments and on hospital wards. al diagnosis and throughout their treatment. In 2023, we supported 583 people1199 in 20221, in person and by phone as needed by the hospitals. We ran 39 support groups {in person, hybrid and online only) supporting 2,397 people in 202311,911 in 20221. Our specialist online support groups are well received especially by those wth rarer leukaemias. We also ran an online forum via Healthunlocked and closed Facebook groups that collectively supported 4,900 14,333 in 20221 people. Our buddy service matches patients and families with people who have a similar diagnosis for emotional support. In 2023, we matched 148 1131 in 20221 patients for long-temi or short-term buddying wth some volunteer buddies supporting multiple patients. "I had a really good chat with [my buddyj last night and gave me a good insight into what we are both going through. lin really glad that I took up yourseKvice of support." Patient We recognise that a leukaemia diagnosis can have a negative impact on people's finances especially during a cost- of-living crisis. In 2023, wè awarded 819 1465 in 20221 hardship grants of between £100 to £200 and 12 exceptional hardship grants of up lo £1,000. Our Cosl-of-Living grants are run in partnership with Leukaemia UK. Our CART-T Away from Home service provides patients undergoing CAR-T treatment and their families with a￿esS to paid hotel rooms and a £500 grant towards increased costs. This is a partnership Mrith our corporate partner, the Dalata Hotels Group. In 2023. we supported 30 families ￿rith a combination of hotel stays18 with an average stay of 24 days) and financial grants. Our counselling fund provides much needed access to specialist support during a time when NHS counselling resources are stretched or nonexistent. In 2023, we supported 63 people 156 in 20221 seeking support with issues such as bereavement, coping wth a diagnosis either as a patient, parent or child, coping ¥Mth chronic leukaemia, and managing anxiety following a relapse. We believe everyone diagnosed with a potentially life limiting illness such as leukaernia should have the chance lo make a will. In 2023, 61 153 in 20221 people made a wll using our free wlls service with 30 choosing lo leave a gift in their will lo Leukaemia Care although there is no obligation to do so. In 2024, we will continue lo expand our network of hospital hubs lo ensure we support more people at diagnosis and throughout their blood cancer pathway. We wll grow our Information Team and explore how we can make our infomiation more accessible. We wll review our support groups to ensure we reach as many people as possible and for those who cannot allend support groups, offer them a buddy. At a lime when many organisalions struggle lo provide financial grants, we will continue lo provide them while recognising that this is often only a brief respite from ongoing hardship because of a leukaemia diagnosis.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Goal 3- Tackling issues that impact people's lives This area of our work covers our advisory panels (medical and palientl, our patient experience research, our policy and public affairs, campaigns and extemal advocacy projects. Our medical and patient advisory panels provide feedback on not only our strategic plans but also our day-to- day work. We have 82 healthcare professionals including specialists in the four main leukaemias as well as MDS, MPN and rare leukaemias. These include consultant haematologists, clinical nurse specialists, GPS, psychdogists and district general hospital doctors. Our patient advisory panel of 64 indudes acute and chronic leukaemia patients, those with rare leukaemias, MDS and MPN. In 2024, we will investigate new ways of engaging with our panels to ensure that we gather views in a timely manner. This will not be limited to online meetings but also incorporate quick polls and lengthier surveys. We 11 strive lo ensure our patient panels reflect the diverse blood cancer community we serve and offer other opportunities lo volunteer should members feel they no longer wish lo serve on the panels. When faced wth a diagnosis, many will often think about the Impact on a person's physical or mentsl health. Whether Il's time off work for treatment causing a loss of wages, Increased healing bills to wami through the home lo cope wth the effects of treatment or inflated food costs lo help maintain a well-balanced diet, the financial implications are far and wde. These are just some of the hidden costs that come wth a leukaemia diagnosis but are often forgotten about. That's the Leukaemia Levy - the hidden tax, the cost of leukaemia, even when you are being Irealed and cared for by the NHS. In March 2023, we launched our Hashtag Leukaemia Levy campaign lo raise awareness and secure financial support for those affected by a diagnosis. Our three asks were.. a Govemmenl Hospital Travel Fund, an extension lo the support provided by the energy price guarantee and the energy bills scheme and increased financial assistsnce from energy companies. We asked people to show their sUPPOrt by signing a petition 5tsnding behind these asks. We sent a letter lo the Chancellor and Prime Minister, hand-delivering the letters lo their respective doors on Downing Street. Mark Tami MP presented our petition lo the house of Commons asking members lo join us in urging the Government lo provide more support for leukaemia patients. In 2024. we will work with other charities and organisalions collectively lo continue lo address the financial challenges faced by Can￿r patients.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Goal 4- Advancing treatment and care This area Covers our engagement with healthcare professionals - providing training and raising awareness of our services as well as our work on improving access lo treatments. Our Regional Coordinators raise awareness of our services within hospitals across the UK and in 2023, conducted 630 meetings both in person and online to engage with a diverse range of healthcare professionals working with blood can￿r patients. Our coordinators successfully engaged wth 252 health care professionals new to our services. We awarded five bursaries ID nurses seeking lo improve their skill and knowledge of patient care through courses at the Royal Marsden Hospital and Coventry University. We offer eight free online courses for nurses ranging from 1 to 4 hours. Four were removed from arculation pending updates. Topics covered are CAR-T, emergencies in leukaemia, end of life and acute leukaemia, GVHD, sUPPOrtive care, MPNS, understanding blood and its components, diagnosis of leukaemia, and epidemiology, aetiology and risk factors. The average feedback score from users remains consislenlly high 81 4.915 14.2515 in 20221 with 265 new subscribers 1217 subscribers in 20221. In 2024, we wll publish a new course on genetics in acute myeloid leukaemia. Due to resource limitslions, as our courses reach their review dale, they will be removed from circulats.on until they can be updated. In 2023, we launched two new forums for MPN and acute leukaemia nurses alongside our existing chronic lymphocytic leukaemia fotum. In 2023, 126 he8llhc8re professionals 152 in 20221 attended to share updates from scientific and clinical meetings and best piacli¢e in patient care. Leukaemia Care have commilled to be actively involved in all relevant Heath Technology Appraisals for leukaemia, MDS and MPN lo ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. In 2023, we were involved al every stsge of the health technology appraisal prO￿$S in 980/0 of appraisals and were involved in a stage of the process in 1000/0 of appraisals. We secured patient experts for 670h of appraisals with 89% of appraisals also having input from patients via sutveys. Goal S: Creating a narrativ8 to batter reflact tho reality paople face Patient stories, press and social media all play a critical role in ensuring that patients and their families as well as the public understand the reality of living wth leukaemia. Seventy-two people shared their story with us to support others and raise awareness of the challenges they face wth half of these having benefited from our services. Forty-four people keen lo give back and raise awareness of the support available from Leukaemia Care provided testimonies lo be used lo encourage people lo reach out for help. In 2023, we received 147 156 in 20221 pieces of national and 323 1651 in 20221 pieces of regional press coverage with an estimated ￿a¢h of over 1.7 billion11.4 billion in 20221. Our symptoms of leukaemia infomiation and blogs continue lo be our most visited pages on our website especially on swdlen lymph nodes and bruising. An accessibility toolbar has now been deployed on the website which offers translation in over 160 languages as well as accessibility features such as increasing the size of text and an audio ftjnction. In 2024, we will continue to review our webpages focusing on our information for patients through the creation of hubs for different leukaemia types.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Fundraising summary Our approach to fundralslng Leukaemia Care is registered with the FLJndraising Regulator and as such agrees that when ftjndraising will do so in accordance ￿rith Ihe Fundraising Promise and such of the Code of Fundraising Practi￿ as applies to our fundraising methods. We agree to promote the Fundraising Promise Ihlt s'.Ilwww.fundraisin re ulator.or .ukl and to include the Registration Badge Dn our fundraising materials where practical. We are committed to protecting vulnerable people and others from unreasonable intrusion on a person's privacy, unreasonably persistent approaches or undue pressure lo give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly lo the charity about concern5 with our fundraising ask. In 2023, the charity re￿iVed no suppression requests through the Fundraising Preference Service and no fundraising Complaints. Our complaints procedure can be found on our website h s.Ilwww.leukaemiacare.or .uklaboul-usl After concluding 2022 on a positive note, having raised over £2 million for the first lime, 2023 posed fundraising challenges and while fundraising income increased, the costs of raising those funds also saw a significant rise. The positive impact of that further investment in fundraising is expected to be seen in the coming years. Reliable income streams such as legacies and pharmaceutical grants were lower than anticipated, and while we benefited from £165,303 1£411,669 in 20221 from gifts in wills this was a significant decrease when compared to previous years. The Unicornfest art trail was an excellent public event raising awareness of leukaemia and Leukaemia Care, however the return on time invested was lower than expected despite the fact that the auction raised a respectable £146K- the single highest amount raised for the charity in a single day. We had some Suc￿sS with new initiatives such as OLJr first ever matched donation campaign run during Blood Cancer Awareness Month in September made possible by a long-standing supporter and major donor which raised £22,524. Our corporale partnership with Dalata Hotels Groups allowed us to expand our CAR-T Away From Home service as hotel employees worked hard to raise funds. And we exceeded targets in some of our running and challenge events including the London Marathon in which we had 117 runners. Grants and trusts exceeded its target and includes support from Leukaemia UK towards our cost of living with leukaemia grants. We successfully launched our first joint fundraising and support initiative, linking our Bereavement service to In Memory fundraising. This integration resulted in a historical high for In Memory income, exceeding predictions by £25,000. Further growth is anticipated as we strengthen our work In this area. We also started work on our BBC Lifeline appeal which will air in eady 2024 and launched our Christmas giving campaign Snow Much Love. which will run into 2024. Please see below for more detsils on the grants received from the pharmaceutical industry and grants and trusts foundations. In 2024, we will focus on consolidating work done to date focusing on building our legacy, corporate and major donor income. Pharmaceutical grants Leukaemia Care collaborates with the pharma¢euli¢al industry lo ensure that the interests of patients are considered during the development of new drugs and trealmenls. Our patient advisory work plays an important role in making sure Irealmenls are thoroughly appraised and person-￿￿tred before they are made available lo the public. A5 a way of helping us remain secure and lo continue lo be effective In our work wth patients, many phamiaceulical companies providè us wth funding throughout the year. This funding is always received and dispersed strictly within the guidelines laid down by the Association of the British Pharmaceutical Industry IABPII and Leukaemia Care's own Code of Practice (see our website).

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 To ensure that we remain financially independent, limits are placed on all types of grant income. We do not allow the level of funding received from the pharmaceutical industry lo exceed 250/0 of our total annual income, nor do we allow the funding received from any individual company lo exceed 10% of our lolal annual income. In 2023 we were grateful for the followng support from pharmaceutical companies which lolaled £214.472. We also received a further £9,479.11 in honorariums. Please note. this is funding that was received in 2023 - any funding that was intended for 2023 but not re￿iVed until 2024 will be acknowledged in the annual report and accounts for 2024. Abbvie- £15.800 towards improving the accessibility of our Information Programrne Amgen - £5.000 in core funding Astrazeneca UK- £15,000 towards our work in early diagnosis Autolus - £10,000 in core funding Bristol Myers Squibb- £15,000 in core fvnding GlaxoSmithKline- £15,000 towards our Counselling Service Incyie - £15,000 towards our work in early diagnosis Jazz Pharmaceuticals- £20,000 towards our work in earfy diagnosis Kura Oncology - £10,000 In core funding Kyowa Kirin - £5,000 in core funding Novartis- £25,000 towards our work in early diagnosis Pleco Therapeutics- £8,672.27 in core funding Servier- £5,000 in core funding Takeda Pharmaceuticals- £50,000 in core fvnding Grants and trusts Leukaemia Care receives no slalutory funding, but il does receive grant5 from independent Iru5t5 and other funders. These grants are an Increasingly Important part of our income and significantly improve our ability lo deliver services lo leukaemia patients and their families across the UK. We would like lo thank the following funders who kindly plèdged thèir support in 2023. Please note, this is grant funding that was received in 2023 any funding that was pledged for 2023 but not received until 2024 will be acknowledged in the annual report and accounts for 2024. Acute Leukaemia Advocates Ne￿orf TheAlice Ellen Cooper-Dean Charitable Foundation AMW Charitable Trust The Barbour Foundation The Big Life Group Birmingham Hospital Saturday Fund Brighton District Nursing Association Trust The Burford Trusl The C L Lloyd Charitable Trust The de Brye Charitable Trust Doris Field Charitable Trust The Earl Fitzwilliam Charitable Trust The Edward and Dorothy Cadbury Trust The Frank Litchfield Charitable Trust Fullagar Charitable Trust The Helen Jean Cope Charity The J Reginald Corah Foundation Fund The James Tudor Foundation John James Bristol Foundation The Livewell Foundation The Medicash Foundation The Meikle Foundation The Michael and Anna Wx Charitable Ttusl The National Lottery Community Fund The Nisbel Trust Norwich Charitable Trusts The Pennycress Trust Pilkinglon Charities Fund 10-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 The R C Snelling Charitable Trust The Roger & Douglas TurnerTrust The Rothley Trust The Rowlands Trust The Roy Proctor Foundation Santa Barbara Heights Trust Schroder Charitable Trust The Shanly Foundation Sir John Eastwood Foundation The Sovereign Healthcare Charitsble Trust The Squire Patton Boggs Trust Sutton Coldfield Chantsble Trust TheTyne & Wear Community Foundation W A Cargill Fund The W E Dunn Trust The Waller Guinness CharitsbleTrust The Wilmcole Charilrust Grant making by Leukaemla Care Leukaemia Care has five grant making streams.. the Cost of Living with Leukaemia Fund (formerly the Financial Hardship Fund), the Exceptional Hardship Fund, the Leukaemia Counselling Fund. and the CAR-T Away from Home Service Ilaunched in 20221 and nurse bursaries Irelaunched in 20231. These contribute towards addressing the recommendations made in our Living with Leukaemia reports which infomi our strategic aims. Cost of Llvlng wlth Leukaemla Fund This fund provides grants of up to £200 for essential living costs to patients and their families affected by leukaemia, myelodysplastic syndrome IMDSI or myeloproliferative neoplasms IMPNI. There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month. Exceptional Hardship Fund Applicants who have received the Financial Hardship Fund of £200 within the year and are assessed as experiencing exceptional hardship are Considered for an additional grant of up lo £1,000. They are likely to be facing multiple challenges alongside a leukaemia diagnosis such as no recourse lo public funds, homelessness or poor housing, significant mental health issues, care for a disabled dependanl ladull and/or child) etc. The Leukaemla Counselllng Fund We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNS or a parent, sibling, Child or spouse of a patient with a maximum of up lo six sessions of counselling with a maximum award of £400. Counsellors must be registered with the British Association of Counselling and Psychotherapy IBACPI. or the UK Council of Psychotherapy IUKCPI. The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year. CAR-T Away from Home Service CAR-T Ichimeric Antigen Re￿ptOrI cell therapy is a type of treatment for leukaemia that has revolutionized the way leukaemia is treated. It was first approved for B cell acute lymphoblastic leukaemia IALLI but is expected ID change the way other fomis of leukaemia patients are Irealed in the future. The way the therapy is delivered means that patients often have long periods of wailing and spending lime near to hospital to receive the treatment. People can apply for accommodation. grant funding or both ¥Mth one grant per family. This grant is only open lo those ¢urrenlly going through CAR-T therapy and people can apply as soon as they become aware that CAR-T is recommended as a treatment for them. The fund d￿S not have a closing date and funds are allocated on a first- come firsl-served basis until the fund is depleted.

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Thanks lo our hotel partner Dalala, we can offer f￿e accommodation in one double or twin room per family per slay for up to 30 days. This is booked and arranged by Leukaemia Care, and we musl know the dales in advance. This cannot be exchanged for money, vouchers, or another hotel. We will also pay up to £500 in a cash grant to help ￿rith other expenses related to having CAR-T therapy. This could include, but is not limited to travel expenses, increased food costs while away from home etc. Nurse Bursaries Ireintroduced in 20231 This fund provides nurses caring for blood cancer patients up lo £1,000 towards training. education or professional development that enhances the care of patients with leukaemia, MDS or MPN. This could be support with. allending a haematology conference or payment of a module that's part of a Masters degree in a relevant subject. Volunteers Our volunteers play a key role in ensuring that we can offer vitsl support lo those affected by leukaemia, MDS or MPN. For some of our volunteers that involves working directly with those affected lo provide support and guidance, for other volunteers it might b& in supporting our fundraising goals or advising us on the information we produce. Each of our volunteers has their own unique experience and conlribulions, whether they are a patient, a clinician, a carer. or a supporter. 2023 has seen a continuation of the work we started in 2022, building our volunteering program to create a cohesive and highly valuable experience for all volunteers. This has involved continuing to build on the pro￿sses, training and support around each role, alongside including volunteers in new and excib'ng ways. Our biggest volunteering involvement is our Buddy scheme, offering patients and carers one-to-one support with trained buddies who have themselves experienced leukaemia, MPN or MDS. The volunteers are DBS checked, trained and provided wlh ongoing support by both our volunteer coordinator and our Buddy coordinator, who is also a paid employee. The newest role we have Implemented for 2023 has been our Facebook Support Group Moderators. This is a group of volunteers who were given in depth training in moderation of online groups lo allow them lo support us in the running of three of our Facebook groups. The training included guidance on signposting, handling difficult conversations and safeguarding. Patient and clinician volunteers have had a bigger involvement than ever with the reviewing of our patient information, both online and in print. They have been involved in the renewal of our CML and MDS information suites. as well as our new AML genetics booklet. We have increased the points which we get these volunteers involved, allowing them lo influence decisions at a much earfier stsge and continuing to feedback throughout the review process. In addition, we plan lo review the formal of our Patient Advisory Panel in 2024. Our healthcare professional volunteers are a vital resource across the charity, they attend our medical advisory panels, review our patient information, and attend events with us. We are extremely grateful to all of these professionals, and the time they give. Induded in this group are the many nurses who help to run our nationwide support groups ensuring patients do not become isolated because of their diagnosis. They are supported by our network of Regional Ctrordinalors who provide practical, emotional, and administrative support lo the group. Our community fundraising volunteers place collection lins, hold supermarket collections, run events, and join the cheer squad for the London Maiathon. As well as raising funds, they raise awareness of leukaemia and the support we provide within their local communities. Our London Marathon cheer squads were particulady successful, we were able lo gel a large group of dentsl students involved in 2 different cheer squads, introducing Leukaemia Care to future clinical professionals, and giving them an insight into the work we are doing. Our Unicornfest sculpture trail required a large input from volunteers in 2023, we recruited over 50 volunteers, most of whom had no existing connection lo Leukaemia Care, lo assist us in the event across the summer. Volunteers gave their lime once or twice per week in our Unicornfesl shop. assisting stsff with selling official merchandise and unicorn themed goods. Over 30 volunteers got involved on a weekly basis in taking care of the unicorns whilst they were out in public, this involved them looking out for, reporting damage. and keeping their unicorn clean. This role allowed for family volLJnteering, with volunteers getting their children involved with helping them. We also made a connection with a team from Lloyds Bank who participated in a volunteering day of cleaning Ljnicorns across the city and litter picking. The grand finale of Unicomfest saw us involve 43 volLJnteers in the Farewell Festival weekend. 12-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Some feedback from our volunteers". 'It gives your cancer a sense of puryK)se a way to help others, fighting loneliness and misinfonnalion... I've found LC very inclusive of physKal and mental needs. Even more than I've expected. lin physically disabled and neurodivergent and have always fell welcome at LC events and meetings." (Patient Advisory Panel Volunleerl 'Il is very satisfying being &ble lo help p&ople and givg something back after receiving so much from support charities and the NHS. The￿ &fft not many positives lo h&ving leuk&&mia bul being able to use one's pe￿onal experience lo help olh&rs is d&finrf&ly on&., IPatienl Advisor Panel and Buddy) "To get n7e out an(1 improve my mental health and wellbeing, the kids loved taking responsibility for the unicom so was 9￿al they could be involved.. Talking to Othe￿ about our unicom, I had so many friends asking diffe￿￿1 questions abouÉ Éhe trail, shop or skating so I was able to b17ng a lot more people lo the t￿11...60 this with my kids I nom7ally miss out on a lol due lo being a single mum with no chIldca￿ help. Iunicornfesl Mane-tainer Volunteer). Risk assessment and management A Serious Incident Report was submitted to the Charity Commission in January 2023 following a data breach which was also reported lo the Information Commissioners Office IICOI. No further action was taken by either the ICO or the Charity Commission who were satisfied with Leukaemia Care's management of the issue. We carry out an annual detailed review of the charity's activities and produce a comprehensive Ihree-year strategic plan which sets out thè major opportunities for the delivery of patient support. The Trusteès monitor progress against the stratègic objectives set out in the plan quarterly, in addition lo the annual review. As part of this process the Trustees have implemented a risk management strategy, which comprises". a comprehensive annual review lo identify, where possible, the risks which the charity may face during the forthcoming year the eslablishmenl, where possible, of contingency plans lo meet anticipated risklsl the establishment of systems and procedures ID rnltigale such risks and the implementation of procedures to minimise any real or Potential impact Dn the charity should any such risklsl malerialise the prioritisalion of the charity's ath"vities both actual and planned the preparation and monitoring of meaningful and timely financial and management information. The strategic plan referred lo above focuses on the delivery of care and support to anyone affected by blood cancer. Successful implementation of the plan Is dependent upon the chaiily having the necessary resour￿$ available (financial and otherwise) and for the prudent and effective management of such reSoUr￿s. Bul we have also pul in place several other protections beyond this, including". Building organisalional resilience- ensuring coverage of key skill sets, and developing existing stsff wthin and beyond their roles Diversifying income we have sought to create a wide range of income streams, to ensure we are less reliant on the London Marathon Phased investrnenl- al present we have created plans for 2023 and 2024 which include a significant deficit as we seek to grow income. Regular review- by SMT al least monthly and quartedy at Trustee meetings 13-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Our Reserves Policy Leukaemia Care's reserves policy has been developed in line with best practice guidance to maintain resilience rithin the finances of the Charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure. we aim to consider and miligale against financial risk more effectively. We recognise that money is donated to advance our charitable purposes. As such, Dur policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily. Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial retum, preserving capital value, and meeting unanlicipaled cash flow requirements. For the purposes of investment, Leukaemia Care has divided Ils reserves Into two those expected to be held for a long-term time horizon and those that may be needed in the short temi. It is Leukaemia Care's policy lo express reserves in terms of 'months of expenditure, for the purposes of external communications. Our policy identifies three factors requiring the charity to hold reserves. These are Considered in the context of both individual risks and by summation Ilhe addition of multiple risks happening at once).. i. Liabilities and contingencies - i.e. staffing costs to provide services, wnd4own costs based on the cosls of closing down the Charity. ii. Provision lo absorb setback- i.e. predominantly related lo income-based risk. iii. Funds designated for specific commitments- i.e. operational plan commitments, including forecast deficits or existing committed projects and activities. In line with the considerations above, Leukaemia Care's policy is lo hold sufficient funds lo cover between six lo nine months of budgeted ongoing expenditure. Ongoing expenditure excludes on&off projects and depreciation, which are mel through designation. Our policy is subject lo annual review by the board of Trustees, with the reserves reviewed in line with the policy at budget seth.ng lime and in lime for the new financial year. Notwithstanding this, the reserves amount is calculable at any point of the year if required, as the financial position of the charity changes or plans aller. Our Investment Policy The Trustee Board regularty monitors cash and investments against objectives and risk profile. The investment policy is reviewed annually, and recommendations made to Trustees. Day-tIFday investment management is delegated lo an authorized, professional investment advisor, regulated by the FCA. Our investment policy aims lo pioduce the best financial rètum within an acceptable level of risk. The investment objective for the long-term reserves is lo generatè a return in excess of inflation over the long term bul also lo be available al short notice lo support the on-going activities of Leukaemia Care. The investment objective for the short-lerm reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements. 14-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Structure, governance and management Constitution This is the fourth annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No." 119117521. 11 was then registered with the Charity Commission on 13 June 2019 (Registered No.. 11838901 and with the Scottish Charity Regulator on 9th December 2019 (Registered No. SC0498021. Trustees and their role The trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 trustee5 in office at any one b.me are required by the constilulion. Al each AGM one-third of the trustees, must retire from office bul may sland for re-election. A Trustee's term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel lo trustee meetings. The trustèes meet six times a year Icurrenlly online or hybrid meelingsl and delegate day-lfrday running of the charity lo the senior management team. The Trustees who served during the year and up lo the date of signature of the financial slalements were.. Mr Christopher R G Matthews-maxwell (Chairl Mrs W J Davies (freasurerl Dr Emmanouil Nikolousis Ms E Wilson (Vice Chairl Ms Kate Slallard Mr Robert Heppell Mr Dharmesh Mehta Professor Mhairi Copland Ms Carina Patterson Helen Knight Dr Sarah Seade Recruitment, induction and training of Trustees The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board lo deliver the charity's Strategy. A volunteer role specification 15 drafted and approved before being advertised as widely as possible. This includes Leukaemia Care's social media oullels, online recruitment siles, specialist publicab.ons targeting for example healthcare professionals as well as a direct approach lo individuals identified as having the appropriate skill sets. Potential applicants are Invited lo submit a CV and if shortlisled for Interview, will be Interviewed by the Chair and another trustee. Successful applicants will be ¢o-OPted as trustees until their formal election al the next annual general meeting. On appointment, the new Trustees attend an induction al our offi￿$ in Worcester with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack inclLJding a copy of the constitution, recent trustee board minutes. accounts. financial repotts, the charity's strategy as well as helpful publications such as the Charity Commissions "The essential trustee" All Trustees are encouraged to attend Leukaemia Care's webinars for further insight into the challenges facing patients, their loved ones and the healthcare professionals that look after them. and how Leukaemia Care is addressing them. 15-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Our trading subsidiary Ahead of the launch of our art trail Unicomfesl, the Trustees of Leukaemia Care Limited decided lo register a trading subsidiary - Leukaemia Care Trading Limited which was registered at Companies House on 21 April 2022 (Registered No.. 140593891. Ils Directors are Chris Matthews-maxwell, Elizabeth Wilson and Wendy Davies who are also the Chair, Vice Chair and Treasurer of the parent charity. Leukaemia Care Limited. All trading activities relating lo Unicomfesl will go through the subsidiary company. Senior management team The Trustees delegate day-to4ay operations of the charity to the executive team. In 2023, Zack resigned to take up a new role in the corporate sector, and Monica and Nicole stepped in as joint interim CEOS until Colin started in April 2024. Chief Executive Officer (J"oined 2 April 20241 Colin Dyer Chief Executive Officèr (left 30 November 20231 Zack Pemberton-W)ileley Chief Operating Officer and Deputy CEO Monica Izmajlowicz Communications and Fundraising Director Nicole Scully Our Patrons We are very grateful for the wami support of our patrons, Lady Penny Mountbatten and Beverfey Worboys. Our Presldent and Vl¢e-Presldents Our Vice Presidents ably led by Dr Taylor represent our history as well as taking part in adivities such as chairing our ¢onferen¢es, Conlribuling via our medical advisory panels, raising awareness of leukaemia and fundraising. President Dr Richard Taylor Vice Presidents Ms. Sue Merchant Professor Claire Harrison Dr Robert Marcus ProfessorAnlonio Pagliuca Ms Sheila Hegaty Mr Jason Eliadis Mr Roland Maturi Mrchristopher Matthews-maxwell Mr Peter Mondon MrAnthony Gavin 16-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Medical advisory panels Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish lo thank them for their time. Acute I ho ic leukaemia anel Prof. Adele Fielding Dr. Anthony Moorman Prof. Oliver Ottmann Dr. Nick Morfey Dr. Sara Ghorashian Prof. Ajay Vora Dr. Tobias Menne Dr. Claire Rownlree Acute m eloid leukaemia nel Prof. Mary Frances Mcmullin Dr. Steve Knapper Prof. Rachael Hough ISCT adolescent leukaemial Dr. David Taussig Dr. Priyanka Mehts IAML& CMLI Dr. Panagiolis Kottaridis Dr. Mike Dennis Dr. Ann-Louise Latif Prof. Nigel Russell hr ni Assoc. Prof. Anna Schuh Prof. Chris Fegan Prof. GLJY Pratt Assoc. Prof Francesco Forconi Prof. Adrian Bloor Dr. Shankara Paneesha Dr. Alison Mccaig Dr. Niamh Appleby Dr. George Follows Prof. Christopher Fox Prof. John Gribben Dr. Nicolas Martinez-calle Chronic m eloid leukaemia anel Dr. Dragana Milojkovic Prof. Jane Apperley Prof. Stephen O'Brien Prof. Mhairi Copeland Dr Jonathan Kell Dr. Nilima Parry-Jones Dr. Piers Patten Dr. Renats Walewska Dr Sunil Lyengar 17-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Other blood cancers nel Prof. Claire Harrison IMPNI Dr. Claire Dearden IHCLI Dr. Richard Kelly (Aplastic anaemia, MDS) Prof David Bowen IMDSI Dr Dima El-shakari ILGLL, ALL, CLLI Prof. Rachel Hough Prof. Adam Mead GP adviso Panel Dr. Rebecca Chellaswamy Dr. Elaine Hampton Dr. Tom Kneale Dr. Anish Kotecha Dr. Lily Lamb Dr. Rachael Marchant Dr. Pawan Randev Dr. Richard Roope Dr. Lance Saker Dr Sarah Smith Isearfel Dr. Neil Smith Dr. Sarah Taylor Prof. David Weller Nurse adviso anel Sarah Blakey Alicia Harris Joanna Large Catherine Langton Sarah Watmough Jacqueline Stones Joanna Stokes Alison Pugh Phyllis Paterson Lianne Palmer Aileen Nield Klara Matulay Laura Ledger Helen Knight Caroline Kerr Michelle Kenyon Tracy Gunter Catherine Griffilhs Kirsty Crozier Marife Colis Andrea Woollorton Aine Sheerin O'Neil Jackson Alice Ryan Bryony Tyrell Claire Ballantyne Sheri Thompson Tina Brooks Alison York Matthew Fowler Christina Kirby Eleanor Pearce Catherine Chapple 18-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Remuneration policy Leukaemia Care is Committed lo paying our staff faidy and in a way lo attract and relain the skills needed lo deliver our vision and mission effectively. When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed lo avoiding discrimination. including bul not limited to the grounds of protected characteristics as set out in the Equality Act 2010. The Board of Trustees are responsible for setting remuneration levels for the senior management team,. CEO, COO and Communications and Fundraising Director. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this Policy. Leukaemia Care upholds a policy that the full-lime equivalent ratio for remuneration betr￿een ils highest paid member of stsff and the median salary level will not exceed 3..1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage. The remuneration policy is reviewed annually by Trustees, normally al their meeting in November. Salaries are reviewed annually in March following annual appraisals and lake effect from April. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health. )en setting remuneration levels for job roles wthin Leukaemia Care, we consider the following factors." Mission and strategic aims of the charity and ils general day-t(>day needs. Consistency of equivalent roles across the Charity and how any decision might irnpact on the overall remuneration policy. Skills, experience, expertise, and competencies, and any significant changes in job descriptions or duties. Current strategic business plan and how this might affect current andlor future needs. Leukaemia Care's financial ability lo pay. Available information on charitable sector pay levels, alongside that of other sectors. Available information on regional pay levels The nature of the wider employment offer the charity can make where pay is only part of the package and can include opportunities for personal development. The charity's track record in recruiting and retaining high-perfomiing staff. The potential impact of any decision on the charity's reputation with beneficiaries, donors and the wider putAic. Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO. As part of our commitment to transparency, information regarding the salary bandings will be made available lo all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale. The Board of Trustees is committed lo including the following information wthin ils annual ststulory report and financial 5talemenls". A summary stslemenl of the charity's remuneration policy and approach to senior management pay. Disclosures on the number of staff in receipt of more than £60,000 per annum lin bands of £10,000). and the collective lolal benefits lincluding pension payments and employer's national insurance) paid lo the Senior Management Team, in line with the accounting Slalemenl of Recommended Pradice 2019 for charities. Given the ¢harily's size. the Board of Trustees does not believe it is appropriate to disclose the actual salary of any individual member of stsff, including that of the senior management team, to the public. 19-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Pensions The charity will match employee contributions up to 70k of qualifying earnings to the government workplace scheme NEST. Related parties In addition lo the trading subsiLYi8ry undertaking, Leukaemia Care Trading Limited, the only related parties are the Trustees and those individuals connected with them including family membeis, business associatès and other charities in which they are involved. Please refer to note 12 in the financial slalements for detail. Auditor In accordance with the company's artides, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be pul al a General Meeting. Disclosure of inforniation to auditor Each of the Iruslees has confirmed that there is no infomialion of which they are aware which is relevant lo the audit, bul of which the auditor is unaware. They have further confirmed that they have taken appropriate steps lo identify such relevant infomiation and lo establish that the auditor is awa￿ of such information. The trustees. report was approved by the Board of Trustees. Mr Christopher R G Matthews-maxwell (Chairl Trustee 7/4/2024 Dale.. -20-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE STATEMENT OF TRUSTEES, RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEMBER 2023 The Iruslees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees, Report and the financial statements in accordance with applicable law and United Kingdom Accounting Stsndards (United Kingdom Generally Accepted A¢¢ounling Practice). Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year. In preparing these financial statements, the trustees are required to.. select suitable accounting policies and then apply them consistently., observe the methods and principles in the Charities SORP., make judgements and estimates that are reasonable and prudent., and prepare the financial slalemen15 on the going concem basis unless it is inappropriate lo presume that the charitable group wll continue in operation. The trustees are responsible for keeping adequate accounting records that disclose with reasonable a￿uraCY al any lime the financial position of the charitable group and enable them lo ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment Iscotlandl Act 2005 and the Charities Accounts Iscollandl Regulations 2006 las amended). They are also iesponsible for safeguarding the assets of the charitable group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustee5 are responsible for the maintenance and integrity of the charity and financial information included on the charitable group's website. Legislation in the United Kingdom goveming the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 211

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE Oplnlon We have audited the financial statements of Leukaemia Care (the 'charitable group'l for the year ended 31 December 2023 which comprise the statements of financial activities, the balance sheets and the statement of financial activities, the balan￿ sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparatlon is applicable law and United Kingdom Accounting Stsndards, Including Finanaal Reporting Standard 102 The Financial Reporting standa￿ applicable in the UK and Republic of I￿land (United Kingdom Generally Accepted Accounting Prath"cel. In our opinion, the financial statements.. give a true and fair view of the slate of the charitable group's affairs as at 31 December 2023 and of ils incoming resour￿ and application of resources, for the year then ended," have been propedy prepared in accordance with United Kingdom Generally Accepted Acwunting Practice., and have been prepared in accordance with the requirements of the Companies Act 2006. the Charities and Trustee Investment IS¢otlandl Act 2005 and regulation 8 of the Charities Accounts Iswuandl Regulations 2006 las amended). Basls for oplnlon We conducted our audit in accordance wth Intemational Standards on Auditing IUKI IISAS IUKII and applicable law. Our responsibilities under those standards are further described in the Aiiditorfs responsibililies for the audit of the financial statements section of our report. We are independent of the charitable group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Concluslons relatlng to golng Concern In auditing the financial statements, we have concluded that the trustees. use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubl on the charitable group's ability lo continue as a going concern for a period of at least twelve months from when the financial statements are aulhorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. other information The other infomialion comprises the information included in the annual report other than the financial statements and our auditor's report Ihereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other infotmation and we do not express any form of assurance conclusion thereon. Our responsibility is lo read the other information and, In doing so, consider whelhei thè other Information is materially inconsislenl with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears lo be materially misstated. If we identify such material inconsistencies or apparent material misslatemenls, we are required lo determine whether this gives rise lo a matèrial misslalement in the financial statements themselves. If, based on the work we have performed, we conclude that the￿ is a material misslalemenl of this other infomiation, we are required to report that fact. We have nothing to report in this regard. -22-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE Matters on whlch we are requlred to report by exceptlon We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotlandl Regulations 2006 las amendedl require us to report to you if, in our opinion.. the information given in the financial slalemenls is inconsistent in any material ￿SpeCt with the trustees, report", or suffiaenl and proper accounting records have not been kept,. or the financial statements are not in agreement wth the accounting records., or we have not received all the information and explanations we require for our audit. Responsibilities of trustees As explained more fully in the statement of trustees, responsibilities, the trustees, who are also the diTeclors of the charitable group for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such Intern81 control a5 the Ituslees determine Is necessary lo enable the preparation of financial slalements that are free from material misslatemenl, whether due lo fraud or error. In preparing the financial slalemenls, the trustees are responsible for assessing the charitable group's ability to continue as a going concem, disclosing, as applicable, matters related to going ¢oncem and using the going concern basis of accounting unless the trustees either intend lo liquidate the charitable group or lo cease operations, or have no realistic allernalive bul to do so. Auditorfs responsibilities for the audit of the financial statements We have been appointed as auditor under section 144 of the Charities Act 2011 and section 4411 Ilcl of the Charities and Trustee Investment (Scollandl Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder. Our objectives are lo obtain reasonable assurance about whether the financial slalements as a whole are free from material misslalement, whether due lo fraud or error, and to Issue an auditor'5 report that includes our opinion. Reasonable assuiance is a high level of assurance but is not a guarantee that an audit conducted In accordance th ISAS IUKI will always delecl a material misslalement when il exists. Misslalements Can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial slatemenls. The extent to which our pro￿ureS are capable of detecting irregularities, including fraud, is detailed below. Exlent to whlch tha audlt was considorgd capab19 of detecting Irregularities and fraud an understanding of the risk assessment process lincluding the assessment of the risk of fraud) adopted by the Board is obtained and their attitude to risk ascertained an assessment of the susceptibility to material mis-statement of the financial slalements as a result of management over-ride or fraud is made a review of the fundraising complaints register is undertaken and the matters arising assessed as to the existence of fraud and irregularities il is ensured that the engagement team have, collectively, the appropriate competence, capabilities and skills lo be involved in the assignment, arè fully briefed and understand the risks specific lo the charitable group Audit response to risks identified processes ID lesl the outcomes of our assessment include, a review of Board minutes, analytical review, the relevance and accuracy of significant accounting eslimales, substantive lesling of significant Iransaclions, work to identify unusual or unexpected accounting entries including the lesling of journal entries, Information disclosed in the financial statements is traced lo supporting documentslion. In all instances il is acknowledged that material mis- slalemenls that arise from fraud may involve deliberate concealment or collusion and are, therefore, by their very nature harder lo delecl than those arising from error. -23-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE il is estsblished if there have been any instsnces of non<ompliance with applicable laws and regulations, where there are such breaches, a full understanding. including gathering of relevant documentslion appertaining to the event is obtained and assessed It should be noted that Auditing standards limit the audit procedures required lo identify non-compliance wlh laws and regulations lo enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any. A further description of our responsibilities is available on the Financial Reporting Council's website al.. https'.11 www.frc.org.uklaudilorsresponsibililies. This description forms part of our auditorfs report. Use of our report This report is made solely to the Charity's Iruslees, as a body, in accordan￿ with part 4 of the Charities (Accounts and Reportsl Regulations 2008 and regulation 10 of the Charities Accounts (Scotlandl Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not ac￿pt or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed. Ellzabeth Needham ACA CTA IVATI (Senlor Statutory Audltorl for and on behalf of Kendall Wadley LLP Q58A98DIDOD3483 . 04/0712024 Chartered Accountants Statutory Auditor Granla Lodge 71 Graham Road Malvern Worcestershire WR142JS Kendall Wadley LLP is eligible for appointment as auditor of the charitable group by virtue of its eligibilty for appointment as auditor of a company under section 1212 of the Companies Act 2006. -24-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2023 Unrestricted Restricted funds funds 2023 2023 Total Unrestricted Restricted funds funds 2022 2022 Total 2023 2022 Notes Income and endowments from: Donations and legacies Trading income Fundraising income Investments Other income 591,126 150,900 1,237,052 34,057 983 249,151 840,277 150,900 1.237,052 34,057 963 836,570 193,750 723,517 43,352 901 341,404 1,177,974 193,750 723,517 43,352 901 Totsl Income 2,014,098 249,151 2,263,249 1,798,090 341,404 2,139,494 Ex endlture on.. Raising funds 1,445,705 1,445,705 784,794 784,794 Charitable activities 1,158,403 256,727 1,415,130 937,681 257,067 1,194,748 Totsl expendlture 2,604,108 256,727 2,860,835 1,722,475 257,(￿7 1,979,542 Net gainslllossesl on investments 16 30,632 30,632 177,2211 177,2211 Net loutgolng}Ilncomlng resources 1559,3781 17,5761 {566,9541 11,6061 84,337 82,731 Other recognised gains and losses Revaluation of tsngible fixed assets 12,640 12,640 12,640 12,640 Net movernent in funds 1546,7381 17,5761 {554,3141 11,034 84,337 95,371 Fund balances at 1 January 2023 2,971,488 155,918 3,127,4C 2,960,454 71,581 3,032,035 Fund balances at 31 December 2023 2,424,750 148,342 2,573,092 2,971,488 155,918 3,127,406 The statement of financial activities indudes all gains and losses recognised in the year. All income and expenditure derive from continuing aclivilies. The slalemenl of financial activities also complies wth the requirements for an incorne and expenditure account under the Companies Act 2006. -25-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE STATEMENT OF FINANCIAL ACTIVITIES - CHARir( INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2023 Unrestricted Restricted funds funds 2023 2023 Total Unrestricted Restricted funds funds 2022 2022 Total 2023 2022 Notes Income and endowments from: Donations and legacies Fundraising income Investments Other income 591,126 1,237,052 34.057 963 249,151 840,277 1,237,052 34,057 963 836,570 794,529 43,352 901 341,404 1,177,974 794,529 43,352 901 Total income 1,863,198 249,151 2,112,349 1,675,352 341,404 2,016,756 Ex enditure on.. Raising funds 1,092,990 1,092,990 662,056 662,056 Charitable activities 1,158,403 256,727 1,415,130 937,681 257,067 1,194,748 Material other expenditure 14 202,130 202,130 Totsl expendlture 2,453,523 256,727 2,710,250 1,599,737 257,067 1,856,804 Net gainslllossesl on investments 15 30,632 30,632 177,2211 177,2211 Net loutgoing}lincoming resources 1559,6931 17,5761 {567,2691 11,6061 84,337 82,731 Other recognised gains and losses Revaluation of tsngible fixed assets 12,640 12,640 12,640 12,640 Net movement in funds 1547,0531 17,5761 {554,6291 11,034 84,337 95,371 Fund balances at 1 January 2023 2,971,488 155,918 3,127,4( 2,960,454 71,581 3,032,035 Fund balances at 31 December 2023 2,424,435 148,342 2,572,777 2,971,488 155,918 3,127,406 The statement of financial activities indudes all gains and losses recognised in the year. All income and expenditure derive from continuing aclivilies. The slalemenl of financial activities also complies wth the requirements for an income and expenditure account under the Companies Act 2006. -26-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE CONSOLIDATED BALANCE SHEET AS A T31 DECEMBER 2023 2023 2022 Notes Fixed assets Tangible assets Investments 17 18 887,448 646,130 879,550 611,708 1,533,578 1,491,258 Current assets Stocks Debtors Investments Cash at bank and in hand 20 21 22 8,435 306,117 206,482 629,819 35,404 407,042 403,520 961,507 1,150,853 1,807,473 Creditors: amounts falling due within one year 23 {111,3391 {171,3251 Net current assets 1,039,514 1,636,148 Total assets less current liabilities 2,573,092 3,127,406 Income funds Restricted funds Unrestricted funds Designated funds General unreslricled funds 25 148,342 155,918 26 1,114,976 1,309,774 1,347,823 1,623,665 2,424,750 2,971,488 2,573,092 3,127,406 -27-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE CONSOLIDATED BALANCE SHEET (CONTINUED) ASA T31 DECEMBER 2023 The company is entitled lo the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023, although an audit has been carried out under section 144 of the Charities Act 2011. The directors acknowledge their responsibilities for complying wth the requirements of the Companies Act 2006 th respect to accounting records and the preparation of financial slalemenls. The members have not required the company to obtain an audit of ils financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with sects.on 476. These financial statements have been prepared in accordance with the provisions applicable lo companies subject to the small companies regime. The financial statements were approved by the Trustees on 26 June 2024. Dtsous*nidby.' 4LS 4CF471gFQE4E433.- PAD￿¢13￿4￿.- Mr Christopher R G Matthews-maxwell (Chairl Tru$t90 Mrs W J Davies (Treasurer) Trustso Company registration number 11911752 -28-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE CHARITY BALANCE SHEET AS A T31 DECEMBER 2023 2023 2022 Notes Fixed assets Tangible assets Investments 17 18 887,448 646,230 879,550 611,808 1,533,678 1,491,358 Current assets Stocks Debtors Investments Cash at bank and in hand 8,435 301,802 206,482 629,819 6,225 396.851 403,520 961,507 21 1,148,538 1,768,103 Creditors: amounts falling due within one year 23 1107,4391 {132,0551 Net current assets 1,039,099 1,636,048 Total assets less current liabilities 2,572,777 3,127,406 Income funds Restricted funds Unrestricted funds Designated funds General unreslricled funds 25 148,342 155,918 1,114,976 1,309,459 1,347,823 1,623,665 2,424,435 2,971,488 2,572,777 3,127,406 -29-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE CHARITY BALANCE SHEET (CONTINUED) ASA T31 DECEMBER 2023 The company is entitled lo the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023, although an audit has been carried out under section 144 of the Charities Act 2011. The directors acknowledge their responsibilities for complying wth the requirements of the Companies Act 2006 th respect to accounting records and the preparation of financial slalemenls. The members have not required the company to obtain an audit of ils financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with sects.on 476. These financial statements have been prepared in accordance with the provisions applicable lo companies subject to the small companies regime. The financial statements were approved by the Trustees on 26 June 2024. DocuSWby'. 4LS Mr Christopher R G Matthews-maxwell (Chairl Tru$t90 Mrs W J Davies (Treasurer) Trustso Company registration number 11911752 30-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2023 2023 2022 Notes Cash flows from operating activities Cash labsorbed byllgeneraled from operations 1525,6321 223,094 Investing activities Purchase of tangible fixed assets Purchase of investments Proceeds from disposal of investments Other investment movements Investment income received 133,3601 1118,5181 111,022 3.705 34,057 132,0341 189,2471 57,573 8,298 40,580 Net cash (used inllgenerated from investing activities 13,0941 5,170 Net cash used in financing activities Net Idecreaselllncrease In Cash and cash equlvalents 1528.7261 228,264 Cash and cash equivalents at beginning of year 1,365,027 1,136,763 Cash and cash equivalents at end of year 836,301 1,385,027 Relating to: Cash al bank and in hand Short term deposits included in current asset investments 629,819 961,507 206,482 403,520 311

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Accountlng pollcles Charity information Leukaemia Care is a private company limited by guarantee incorporated in England and Wales. The registered office is One Birch Court, Blackpole East. Worcesler, VVR3 8SG. 1.1 Accounting convention The financial stslemenls have been prepared in accordan￿ with the charitable group's Igoveming documentl, the Companies 2006. the Charities and Trustee Investment IS¢otlandl Ad 2005, the Charities Accounts (Scotlandl Regulations 2006 las amended). FRS 102 °The Financial Reporting Standard applicable in the UK and Republic of Ireland I'FRS 102.1 and the Charities SORP 'Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191. The charitable group is a Public Benefit Entity as defined by FRS 102. The financial slalemenls are prepared in sterling, which is the functional currency of the charitable group. Monetsry amounts in these financial stslemenls are rounded lo the nearest £. The financial statements have been prepared under the historical ¢osl convention, modified to include the revaluab.on of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are sel out below. 1.2 Business combinations In the parent company financial stslemenls, the cost of a business Combination is the fair value at the acquisition dale of the assets given, equity instruments issued and liabilities incurred or assumed, plus Costs directly attributable lo the business combination. 1.3 Basis of consolidation The consolidated group financial ststemenls consist of the financial ststemenls of the parent company Leukaemia Care together wth all entities controlled by the parent company (its subsidiariesl. All financial slalemenls are made up lo 31 December 2023. Where necessary, adjustments are made lo the financial statements of subsidiaries lo bring the accounting policies used into line with those used by other members of the group. All inlra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on Consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Subsidiaries are consolidated in the group's financial statements from the date that control commences until the dale that control ceases. 1.4 Going concem At the time of approving the financial statements. the trustees have a reasonable expectation that the charitable group has adequate resources to continue in operational existence for the foreseeable fLJture. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements. 1.5 Charitable funds Unreslricled funds are available for use at the discretion of the trustees in furtherance of their charitable objectives. Restricted funds are subject lo specific conditions by donors as lo how they may be used. The purposes and uses of the restricted funds are sel out in the notes to the financial statements. 32-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Accounting policies (Continued) Endowment funds are subject lo specific conditions by donors that the capital musl be maintained by the charitable group. 1.6 Income Income is recognised when the charitable group is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and il is probable that income will be received. Cash donations are recognised on receipt. Other donations are recognised once the charitable group has been notified of the donation. unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation. Legacies are recognised on receipt or olherwse if the charitable group has been notified of an impending distribution, the amount is known, and re￿Ipt is expected. If the amount is not known, the legacy is treated as a contingent asset. 1.7 Expenditure Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party. il is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably. Expenditure is classified by adivity. The costs of each activity are made up of the lolal of direct costs and shared costs. including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use. All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised al point of expense. Costs are allocated lo a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs diredy attributsble to raising funds through aclivilies. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable aclivits.es and govemance costs based on estimate of stsff lime attributable lo each. 1.8 Tanglble fixed assets Tangible fixed assets are initially measured al cost and subsequently measured at cost or valuation, nel of depreciation and any impairment losses. Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases.. Freehold buildings Compuleis and other equipment Fixtures and fittings Over 50 years over 3 or 4 years over 10 years 33-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Accounting policies (Continued) Freehold land is not depreciated. The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the ststemenl of financial ath"vities. The charity has no specific value above which it capitslises assets. Assets are capilalised when they are held for long term use. 1.9 Flxed asset Investments Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured al fair value al each reporting date. Changes in fair value are recognised in nel incomellexpenditurel for the year. Transaction costs are expensed as incurred. 1.10 Impaimient of fixed assets Al each reporting end dale, the Charitable group reviews the Carrying amounts of its tangible assets to detemiine whether there is any indication that those assets have suffered an impaimienl loss. If any such indication exists, the recoverable amount of the asset is eslimaled in order to determine the extent of the impairment loss lif any). 1.11 Stocks Stocks are stated at the lower of cost and estimated selling pri￿ less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost. Nel realisable value is the estimated selling price less all estimated costs of completion and costs lo be incurred in marketing, selling and dislribulion. 1.12 Cash and cash equivalents Cash and cash equivalents include cash in hand, deposits held al call with banks, other short-lerm liquid investments with original maturities of three months or less. 1.13 Flnanclal Instruments The charitable group has elected to apply the provisions of Section 11 'Basic Financial Instruments, and Section 12 '0ther Financial Instruments Issues, of FRS 102 to all of ils financial inslrumenls. Financial Instruments are recognised in the charitable group's balance sheet when the charitable group becomes party lo the contractual provisions of the Instrument. Financial assets and Iiabililies are off5el, with the net amoun15 presented in the financial slatemenls, when there is a legally enforcèable right lo sel off the recognised amounts and there is an Intention lo selllè on a nel basis or lo realise the asset and settle the liability simultaneously. Basic financial assots Basic financial assets, which include debtors and cash and bank balances, are initially measured al transaction price including transaction Costs and are subsequently carried at amortised cost. Financial assets classified as receivable within one year are not amortised. 34-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Accounting policies Icontinuedl Basic financial liabililies Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised. Trade creditors are obligated to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are dassified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost. Derecognition of financial liabilities Financial liabilities are derecognised when the charitable group's contractual obligations expire or are discharged or cancelled. 1.14 Employee bengflts The cost of any unused holiday enlillemenl is recognised in the period in which the employee's services are received. Termination benefits are recognised Immediately as an expense when the charitable group is demonstrably committed lo terminate the employment of an employee or lo provide lerminalion benefits. 1.1S Retirement benefits Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due. Critical accounting estimates and judgements In the application of the charitable group's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The eslimales and underlying assumptions are reviewed on an ongoing basis. Revisions lo accounting eslimales are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods. As described above, the Iruslees annually exercise judgement through consideration of the carrying value of the freehold buildings held by the charity. Adjuslmenls are made through the Slalemenl of Financial Activities for Changes in value determined by the review process. 35-

(TJ ts) CO Its (O ¢D 10 0￿0 o) (TJ o r W) ¢D

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Tradlng In¢om9 Group Trading Trading subsidiary subsidiary 2023 2022 Sales 150,900 193,750 Fundraising income Group Unrostricted Unrestricted funds funds 2023 2022 Fundraising events 1,237,052 723,517 Charity Unrestricted Unrestricted funds funds 2023 2022 Fundraising events 1,237,052 794,529 Investments Group and charity Unrestricted Unrestricted funds funds 2023 2022 Rental income Investment income Interest receivable 6,475 9,452 18,130 25,900 7,380 10,072 34,057 43,352 37-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 other Income Group and charity Unrestricted Unrestricted funds fund$ 2023 2022 Solar panels 963 901 Ralslng funds Group Unrestrl¢t&d Unrestrlctgd funds funds 2023 2022 Fundraisin and ublicil Stsging fundraising events Advertising Other ftjndraising costs staff costs Depreciation and impaimienl Support costs 313,862 48,883 114,340 540,476 4,866 59,767 198,534 43,972 73.022 284,286 4,564 50,504 Fundraising and publicity 1,082,194 654,882 Tradin costs Other trading activities Stsff costs Support costs 261,754 90,961 5,135 79,330 43.408 3,170 Trading costs 357,850 125,908 Investment mana emenl 5,861 4,004 1.445,705 784,794 38-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Raising funds (Continued) Charlty Unrestrlcted Unrestrfcted funds funds 2023 2022 Fundraisin and ubli¢it Stsging fundraising events Advertising Other fundraising costs Stsff costs Depreciation and impaimienl Support costs 313,882 48,883 114,340 540,476 198,534 43,972 73,022 284,286 4,564 50,504 59,767 Fundraising and publicity 1,082,194 654,882 Tradin costs Support costs 5,135 3,170 Trading Costs 5,135 3,170 Investment mana èmenl 5,861 4,004 1,092,990 662,056 39-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Charitable activities 2023 2022 Stsff costs Depreciation and impaimienl Patient Services costs Conferences Help Line costs Leukaemia MatterslNursing Matters 790,994 33,236 112,181 2.126 6,722 34,315 700,036 31,177 63,588 2,256 7,109 28,378 k li Campaign costs Other charitable activities Nurse e-learning tool GP'S e-learning tool Other grants Database costs PalientAdvocacy Website costs Other costs 76,151 6,685 3,056 7,099 155.500 7,037 1,481 32,718 9,159 42,683 18,913 11,0811 5,384 168.054 5,482 116,7241 22,578 2,842 1,278,460 1,080,675 Share of support costs (see note 101 Share of govemance costs Isee note 101 124,689 11,981 106.677 7,396 1,415,130 1,194,748 Analysis by fund Unrestricted funds Reslricled funds 1,158.403 256,727 937.681 257,067 1,415,130 1,194,748 -40-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 10 Support costs Group and charity Support Governance costs costs 2023 Support Governance costs costs 2022 Stsff costs Office costs 22,157 162,299 22,157 162,299 16,753 140,428 16,753 140,428 Audit fees Legal and professional Trustee and meeting expenses 6,600 3,419 6,600 3,419 4,200 3,298 4,200 3,298 7,097 7,097 3,068 3,C68 184,456 17.116 201,572 157,181 10,566 167,747 Analysed be*n Fundraising Trading Charitable activities 59,767 59,767 5,135 136,670 50,504 50,504 3,170 114,073 5,135 11,981 3,170 7,396 124,689 106,677 184,456 17,116 201,572 157,181 10,566 167,747 Govemance costs includes payments lo the auditors of £6,600 12022- £4,200) for audit fees, In addition included in the costs of other trading activities is £3,50012022 - £3,500) in respect of the audit of the financial slalemenls of the subsidiary undertaking. 11 Auditorfs remuneration Fegs payable to tha charitabl& group's auditor and associates.. 2023 2022 Audit of the charitable group's annual accounts 6,600 4,200 In addition £3,500 is payable in respect of the audit of the subsidiary undertaking. 12 Trustees The charity reimburses expenses lo Trustees and management committee member5 for travel, subsistence and telephone relating to charity business. The costs reimbursed lo 212022.. 21 trustees for the current year were £5,74812022 . £2,521). None of the trustees lor any persons ¢onne¢ted wth them) received any remuneration during the year. The charity ulilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a director of this company. The services are provided on an arm's length basis and the amount paid during the year amounted 10 £3,06912022 £2,186). All trustees are covered by an indemnity insurance policy costing £84412022 £8191 411

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 13 Employees The average monthly number of employees during the year was.. 2023 Numbar 2022 Number Training and provision of care Fundraising and publicity Accounts and administration 27 22 20 16 Total 40 Employment costs 2023 2022 Wages and salaries Social security costs Other pension costs 1,298,086 101,407 47,095 930,750 78,226 35,507 1,444,588 1,044,483 The remuneration of key management personnel through payroll and other fees is £204,181 12022 .' £190,0321. The number of employees whose annual remuneration was more than £60,000 is as follows". 2023 Number 2022 Number £60,001- £70,000 14 Material other expenditure Material other expenditure is the write off of the loan ¥Mth Leukaemia Care Trading Limited as this debt is no longer recoverable. 15 Net Ilossesllgalns on Investments Group and charity Unrestrlcted Unrestrlcted funds funds 2023 2022 Revaluation of investsnents Gainlllossl on sale of investments 24,702 5,930 170,1421 17,0791 30,632 177,2211 -42-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 1 S Net Ilossesllgains on investments Icontinuedl 16 Taxation The charity is exempt from lax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the exlenl that these are applied lo its charitable objects. The subsidiary undertakin9 is required to Gift Aid profits arising lo the parent charity such that no tax charge arises. 17 Tanglble flxed assets Group and charity Freehold buildings Computers and Other equlpmeni Flxtures and ffttings Total Cost Al 1 January 2023 Additions Disposals 842,599 276,673 33,360 1183,8691 14,656 1.133,928 33,360 1183,8691 Al 31 December 2023 842,599 126,164 14,656 983,419 Depre¢latlon and Impalmient At 1 January 2023 Depreciation charged in the year Eliminated in respect of disposals Revaluation 241.993 23,996 1183,8691 12,385 254.378 38,102 1183,8691 112,6401 12,640 112,6401 Al 31 December 2023 82,120 13,851 95,971 Carrying amount Al 31 December 2023 842,599 44,044 805 887,448 Al 31 December 2022 842,599 34,880 2,271 879,550 The trustees consider that the value of the freehold propety is not materially different from original cost and the computed depreciation ¢harge for the year is accordingly reversed. -43-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 18 Fixed asset investments Group Listed investments Cash in Other portfolio investments Total Cost or valuation Al 1 January 2023 Additions Valuation changes Other cash movements Loss on disposal Disposals 599,249 118,518 24,702 12121 5,930 1111,0221 12,459 1118,5181 611,708 24,702 3,790 5,930 4,002 111,022 Al 31 December 2023 637,165 8.965 646,130 Carrying amount Al 31 December 2023 637,165 8.965 646,130 Al 31 December 2022 599,249 12,459 611,708 Charlty Listed invastmonts Cash in Othgr portfolio investmants Totsl Cost or valuation Al 1 January 2023 Additions Valuation changes Other cash movements Loss on disposal Disposals 599,249 118,518 24,702 12121 5,930 1111,0221 12,459 1118.5181 100 611,808 24,702 3,790 5,930 4,002 111,022 Al 31 December 2023 637,165 8,965 100 646,230 Carrying amount Al 31 December 2023 637,165 8,965 100 646,230 Al 31 December 2022 599,249 12.459 100 611,808 Other investments represents the interest in the subsidiary undertaking, see note 28. -44-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 19 Flnanclal Instruments Group and charity 2023 2022 Carrying amount of financial assets Instruments measured al fair value through profit or loss 637,165 599,249 20 Stocks Group 2023 Group 2022 Charity 2023 Charity 2022 Finished goods and goods for resale 8,435 35.404 8,435 6,225 21 Debtors Group 2023 Group 2022 Charlty 2023 Charity 2022 Amounts falllng due wlthln one year: Trade debtors Amounts owed by subsidiary undertakings Other debtors Prepayments and accrued income 53,646 183,372 51,266 42,572 137,317 1,759 215,203 2,082 250,389 8,487 215,203 147 250,389 3C6,117 407,042 301,802 396,851 Current asset investments Group and charlty 2023 2022 Unlisted investments 206,482 403,520 23 Crodllors: amounts falllng du9 wllhln ong year Group 2023 Group 2022 Charlty 2023 Charlty 2022 Other taxation and social security Trade creditors Accruals and deferred income 28,981 22,137 60,221 24.912 66,584 79,829 28.981 22,137 56,321 24,912 31,064 76,079 111,339 171.325 107.439 132,055 -45-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Retirement benefit schemes Defined contribution schemes The charitable group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charitsble group in an independently administered fund. The charge lo profit or loss in respect of defined contribution schemes was £47.09512022 - £35,507). -46-

OLfjO ocDo Lfj o ono ooo J o ocro oor) 0￿￿0c00) c￿￿00)￿ (fj O CO o WJ (TJ O WJ ¢00 O Lry Ln Ui ¢0 ¢0 10 (i (n a o) 0 (n Oo rfJz5 ti)>0)￿LL￿()z ts)¥ts)

coTrJ(noooo(N¢DOO fOC)OOrVOO 0￿￿00000(r)_ (o ¢n o r foo0￿j0￿0 ¢7) CD O O io CD O O r ¢D cr Irj Or 000 oott c(ooco oooooot) èai!S-411115111 o000￿000 o Lri o)00 u) oory) Ltsoo- WJCO(n 000 000 0￿0 rOOO 0￿00 Ltsoln Lr) Lnooo OvOOfQO(O (OOOOflOfQOOvOa)f) o c 0> )zJSz(Lo)•<<>¥ts)OuJQUzZousts)Uw)CJ￿<

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 26 Designated funds Group and charity The income funds of the charity include the following designated funds which have been sel aside out of unrestricted funds by the trustees for specific purposes". Balance at 1 January 2022 Transfers Balance at 1 January 2023 Trdnsfer5 B8lan¢eat 31 December 2023 Fixed asset fijnd strategic irnplemelation fvnd 870,617 216,510 8,934 251,762 879,551 468,272 7,897 1240,7441 887,448 227,528 1,087,127 260,696 1.347,823 1232,8471 1,114.976 Fixed assets fund.. The Trustees have agreed lo assign all tsngible fixed assets held with the exception of any which have restrictions imposed upon them lo a general fixed asset designated fund. This was done to ensure that the Charity will have suitsble levels of reserves lo meet ftjlure depreciation costs relating lo these fixed assets and lo recognise the fact that ftjlure depreciats'on Charges ¥MII not directly affect the nel operating capitsl of the Charity. Strategic Implementation Fund.. fLJnds to support the implementation of the bNo-year strategy adopted by the Trustees on 31 January 2024. 53-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 27 Analysls of ngta$$gts bgth9n fund$ Group Unrestricted Restricted funds funds 2023 2023 Total Unrestricted Restricted funds funds 2022 2022 Totsl 2023 2022 Fund balances at 31 December 2023 are represented by". Tangible assets Investments Current asselsllliabililiesl 887,448 646,130 891,172 887,448 646,130 1,039,514 879,550 611,708 1,480,230 879,550 611,708 1,636,148 148,342 155,918 2,424,750 148,342 2,573,092 2,971,488 155,918 3,127,406 Charity Unrestricted Restricted funds funds 2023 2023 Total Unrestricted Restricted funds funds 2022 2022 Total 2023 2022 Fund balances al 31 December 2023 are represented by.. Tangible assets Investments Current asselsllliabilitiesl 887,448 646,130 890,857 887,448 646,130 1,039,199 879,550 611,708 1,480,230 879,550 611,708 1,636,148 148,342 155,918 2,424,435 148,342 2,572,777 2.971,488 155.918 3.127,406 28 Relalod party transa¢tlon$ The charity received £nil 12022 £71,012) from the subsidiary undertaking under a Gift Aid arrangement. There were no other disclosable related party transactions during the year12022 none). 29 Subsidiaries Details of the charitable group's subsidiaries at 31 December 2023 are as fdlows.. Nam9 of und9rtaklng R8glst8rgd office Naturg of bu$lnos$ Class of shares held °fi Held Direct Indirect Leukaemia Care Trading Limited England & Wales Fundraising Ordinary 100.00 54-

DoGUSign Envelope ID." EA4FD9FAA1CB439E.A2B5-B50C3D99EAD2 LEUKAEMIA CARE NOTES TO THE FINANCIAL STATEMENTS ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 30 Cash generated from operations 2023 2022 (Deficilllsurplus for the year 1769,0841 82,731 Adjustments for.. Investment income recognised in statement of financial activities (Gainllloss on disposal of Investrnenls Fair value gains and losses on investments Depreciation and impairment of tangible fixed assets 134,0571 15,9301 124,7021 38,103 {43,3521 7,079 70,142 35,741 Movements in working capital". Decreasellincreasel in stocks Decrease in debtors (Decreasellincrease in creditors 26,969 303,055 159,9861 {35,4041 12,466 93,691 Cash (absorbed byllgenerated from operations 1525,6321 223,094 31 Analysis of changes in net funds The charitable group had no debt during the year. 55-